Harpoon Therapeutics, Inc.
Clinical trials sponsored by Harpoon Therapeutics, Inc., explained in plain language.
A biotech company developing T-cell engager immunotherapies for cancer, now part of Merck.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Tough-to-Treat myeloma: early safety trial of HPN217 begins Results expected Dec 2026 (estimated)
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will tak…
Phase 1/2 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for Tough-to-Treat myeloma: early safety trial of HPN217 begins
Disease control OngoingThis study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also measure how the drug moves through the bo…
Phase 1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC